Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Sample Instructions

Why Now?

More than 100 US medicines' patents expired in 2009 Read More

Clinical & Cost Data

Intelliject studies generate head-to-head data versus the current Standard of Care. View our Clinical & Cost Data

Key patent expiries by 2012:

Zyprexa, Plavix, Seroquel, Lipitor Why Now?

Anaphylaxis Solution Video

To see a video demonstrating how Intelliject's product could theoretically be used in anaphylactic emergency, click here

Loss of Patent Protection

Of the 20 biggest drugs in the world, 18 will lose patent protection in the next five years. Why Now?

Hypoglycemia Solution Video

To see a video demonstrating how Intelliject's product could theoretically be used in hypoglycemic emergency, click here

Why Now?

$1.3 billion to bring a new drug to market in 2009.Read More

Solutions

Intelliject's pipeline targets a number of areas requiring self/caregiver administered injections.Read More

Why Now?

2009-2014: Injectable drug sales will increase by $42 billion. Read More

Patient-Centric

Human Factors Engineering (HFE) is central to ensuring that Intelliject's products are patient-centric Learn More

THIS WEBSITE IS NOT INTENDED FOR PATIENTS OR HEALTHCARE PROFESSIONALS. Members of the public, patients and healthcare professionals should not enter this website. If you are a patient, please see your healthcare professional for more information. This website is intended solely for entities that are current or potential business partners of Intelliject, Inc. Intelliject currently has NO FDA APPROVED PRODUCTS and nothing herein is a promotional therapeutic claim.

All information contained herein is intended to assist interested parties in assessing possible business relationships with Intelliject, Inc. All information is believed to be correct at the date of posting but may change at any time.

I have read the statements above. I am an interested party assessing possible business relationships with Intelliject, Inc.